Uveitis Market Pipeline Review & Analysis, H2 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 3, 2020--
The “Uveitis - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The Publisher’s Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 9, 7, 1, 1, 34 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Reasons to buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3g5bk0
View source version on businesswire.com:https://www.businesswire.com/news/home/20200103005148/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OPTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/03/2020 06:45 AM/DISC: 01/03/2020 06:45 AM